标题
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-30
DOI
10.1038/s41375-020-0996-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Heuser et al. ANNALS OF ONCOLOGY
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- IDH1-R132 changes vary according to NPM1 and other mutations status in AML
- (2019) Brunangelo Falini et al. LEUKEMIA
- FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- 458PSafety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
- (2019) W Wick et al. ANNALS OF ONCOLOGY
- In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
- (2019) Anuhar Chaturvedi et al. LEUKEMIA
- The role of IDH mutations in acute myeloid leukemia
- (2018) Guillermo Montalban-Bravo et al. Future Oncology
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia
- (2018) Phuong-Nhi Bories et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
- (2017) A Chaturvedi et al. LEUKEMIA
- Implementation of a Phase 1 Adaptive Clinical Trial in a Treatment of Type 2 Diabetes
- (2017) Fabián S. Tibaldi et al. DRUG INFORMATION JOURNAL
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
- (2016) A Chaturvedi et al. LEUKEMIA
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
- (2015) Courtney D. DiNardo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Enigmas of IDH mutations in hematology/oncology
- (2015) Michael Heuser et al. EXPERIMENTAL HEMATOLOGY
- Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
- (2013) A. Chaturvedi et al. BLOOD
- Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
- (2013) C. D. DiNardo et al. BLOOD
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
- (2013) J.-A. Losman et al. SCIENCE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started